Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial-Reference-Cited by-同舟云学术

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

Published:2018-05-01 Issue:2 Volume:45 Page:350-359
ISSN:0586-7614
Container-title:Schizophrenia Bulletin
language:en
Short-container-title:

Author:

Brown David¹,Nakagome Kazuyuki²,Cordes Joachim³,Brenner Ronald⁴,Gründer Gerhard⁵,Keefe Richard S E⁶,Riesenberg Robert⁷,Walling David P⁸,Daniels Kristen⁹,Wang Lara¹⁰,McGinniss Jennifer⁹,Sand Michael⁹

Affiliation:

1. Community Clinical Research, Inc, Austin, TX

2. Department of Forensic Psychiatry, National Center of Neurology and Psychiatry, Kodaira, Japan

3. Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

4. Neurobehavioral Research, Inc, New York, NY

5. Department of Molecular Neuroimaging, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

6. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC

7. Atlanta Center for Medical Research, Atlanta, GA

8. CNS Network, Inc, Garden Grove, CA

9. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

10. Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan

Funder